Name | Title | Contact Details |
---|---|---|
Mark Fletcher |
Executive Vice President, General Counsel and Secretary | Profile |
GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.
Soliance is a Allendale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lumos Diagnostics delivers custom diagnostic solutions by combining deep market insight with existing platform technologies, assay development capability and regulated manufacturing experience.
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).
Icon Genetics is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.